ANTENGENE CORP. DL-0001 - Asset Resilience Ratio
ANTENGENE CORP. DL-0001 (722) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of ANTENGENE CORP. DL-0001 to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ANTENGENE CORP. DL-0001's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ANTENGENE CORP. DL-0001 (722) total assets.
Liquid Assets Composition Over Time
This chart breaks down ANTENGENE CORP. DL-0001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ANTENGENE CORP. DL-0001 balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €107.00K | 0.01% |
| Total Liquid Assets | €107.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: ANTENGENE CORP. DL-0001 maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ANTENGENE CORP. DL-0001 Industry Peers by Asset Resilience Ratio
Compare ANTENGENE CORP. DL-0001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for ANTENGENE CORP. DL-0001 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ANTENGENE CORP. DL-0001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | €107.00K ≈ $125.09K |
€1.26 Billion ≈ $1.47 Billion |
+0.00pp |
| 2024-12-31 | 0.01% | €106.00K ≈ $123.93K |
€1.34 Billion ≈ $1.57 Billion |
+0.00pp |
| 2023-12-31 | 0.01% | €105.00K ≈ $122.76K |
€1.62 Billion ≈ $1.89 Billion |
+0.00pp |
| 2022-12-31 | 0.00% | €103.00K ≈ $120.42K |
€2.14 Billion ≈ $2.50 Billion |
-3.74pp |
| 2021-12-31 | 3.74% | €95.74 Million ≈ $111.93 Million |
€2.56 Billion ≈ $2.99 Billion |
-- |
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse lar… Read more